Investor Presentaiton
Revenue (RMBm)
A Track Record of Sustainable and Steady Growth
Turnover and margin evolution since IPO
While our gross margins for 1H2020 declined to 57.8% as a result of product mix changes due to the impact of COVID-19, we expect margins to
recover as COVID-19 stabilizes. We intend to continue our strategy of R&D and product mix upgrades to further enhance our gross margins going
forward.
Proportion of high-value added products and gross profit margins
14,000
63.7% 63.5% 62.2% 62.8% 63.4%
59.1% 58.8% 59.4%
12,000
57.3%
57.8%
55.2% 55.3%
60.0%
53.3%
50.1%
10,000
45.7%
50.0%
42.6%
40.0%
41.1%
8,000
39.8%
40.0%
6,000
40.1%
70.0%
30.0%
40.3%
44.2%
40.4%
4,000
47.2%
38.2% 41.7%
20.0%
47.8%
60.2%
54.2%
59.9%
55.7%
2,000
80.6%
76.6%
59.7%
57.3%
55.8% 59.6%
10.0%
61.8%
58.3%
23.4%
55.4%
52.8%
19.4%
52.2%
54.4%
0
68.0%
132.0%
64.8%
35.2%
44.3%
45.8%
45.6% 44.6% 42.7%
0.0%
2004 2005
2006 2007 2008 2009 2010
2011
2012 2013 2014 2015
2016 2017
2018
2019 1H2019 1H2020
Historical Financials
Restated without
blood purification
Consolidation
of Argon
Gross profit margin
WEGO感高
Proportion of high value-added products
(gross profit margin > 60%)
Proportion of conventional products
(gross profit margin < 60%)
8
Gross profit margin (%)View entire presentation